Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review

Table 2 Pharmacokinetics of currently used direct aging antivirals

DAAs		Absorption				Distribution		Metabolism	Excretion
Tradename	Compound	Tmax (h)	Cmax (ng/mL)	Cmin (ng/mL)	AUC (ng∙h/mL)	Vd/F	Protein binding (%)	Substrate of	T ½, (h)
Zepatier	Elbasvir	3	121	48.4	1920	680	> 99.9	P-gp	31
	Grazoprevir	2	165	18.0	1420	1250	> 98.8	P-gp	24
Epclusa	Sofosbuvir	0.5-1/3	566/868	NR	1260/13970	NR	61-65 minim	P-gp and BCRP	0.5/25
	Velpatasvir	4	311	NR	2970	NR	> 99.5	P-gp, OATP1B, and BCRP	15
Maviret	Glecaprevir	5.0	597	NR	4800	NR	97	P-gp	6-9
	Pibrentasvir	5.0	110	NR	1430	NR	> 99.9	P-gp	23-29
Vosevi	Sofosbuvir	2/4	678/744	NR	1665/12,834	NR	61-65 minim	P-gp and BCRP	0.5/29
	Velpatasvir	4	311	NR	4041	NR	> 99	P-gp, OATP1B1/3, and BCRP	17
	Voxilaprevir	4	192	47	2577	NR	> 99	P-gp and BCRP	33

DAAs: Direct aging antivirals; NR: Data not reported and/or available; T ½: Elimination half time.